Equities Analysts Issue Forecasts for DWTX Q1 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for Dogwood Therapeutics in a note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz forecasts that the company will post earnings of ($0.13) per share for the quarter. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Research also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.40) EPS.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research note on Friday, February 20th. Wall Street Zen cut shares of Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Down 10.8%

Shares of Dogwood Therapeutics stock opened at $2.31 on Thursday. The firm’s 50 day moving average is $2.94 and its 200 day moving average is $4.61. The firm has a market capitalization of $77.16 million, a PE ratio of -0.12 and a beta of 1.90. Dogwood Therapeutics has a 1 year low of $2.26 and a 1 year high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Wednesday, March 18th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.